Israel Active

IDC Herzliya researchers at Israel’s MIGAL laboratory, with Icelandic scientists, have identified that spirulina algae can reduce the cytokine storm that kills Covid-19 patients. The algae was supplied by Israel’s VAXA (Iceland based) who have EU funding to find natural cures for Covid-19.

Israel's Sheba Medical Center is partnering Israel’s Inspira Technologies in trials of its new respiratory treatment for Covid-19 patients suffering from acute breathing difficulties. The Augmented Respiration Treatment (ART) directly oxygenates blood while the patient remains conscious.

Israeli biotech Pepticom (reported previously) has raised $2.6 million to establish a company that can treat SARS-Cov-2 and its mutations. It will implement AI technology to design, discover and develop novel peptide molecules.

One of Israel’s Health Medical Organizations (HMOs) accidentally used a half-sized needle to apply the first Pfizer vaccine into 1,000 Israelis. But when 60% of them were tested three weeks later, they were all found to have high levels of antibodies. The US CDC was pleased to hear the outcome.

Israel’s Health Minister Yuli Edelstein has announced that 90% of Israelis over the age of 50 have been vaccinated or have recovered from COVID-19. 75% of them are eligible for a “Green Pass,” as they had their second vaccine over a week ago or have antibodies after virus recovery.

Israel’s Sheba Medical Center says it is the first hospital in the world to introduce patient-operated devices for hospitalized Covid-infected pregnant mothers to self-monitor their unborn babies. Israel’s HeraBEAT and PulseNmore devices are supported remotely by hospital medics.

Researchers at Israel’s Sheba Medical Center have published the results of their study on medical staff, showing the Pfizer Covid-19 vaccine to be 75% effective two to four weeks after a single shot. Many countries were pleased to know that they were right to prioritize the first shot.

Excellent summary of Israel’s involvement in five highly promising treatments for coronavirus. Also, separate news of Phase 2 trials of the two Covid-19 treatments from Israel’s Redhill.

Israel’s TransAlgae has developed microalgae to deliver oral vaccine powder for animals. Current tests include against diseases affecting fish. Eventually the technology could produce oral vaccines for humans. TransAlgae has signed an agreement with giant French-based Virbac.

Israel’s MyBiotics has partnered Swiss multinational Ferring to use MyBiotics’ microbiome-based treatments for women’s health. The aim of the alliance is to reduce the need for antibiotic use and provide a long-term treatment solution.